These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

154 related items for PubMed ID: 34129290

  • 1. Overall survival in metastatic melanoma correlates with pembrolizumab exposure and T cell exhaustion markers.
    Navani V, Graves MC, Marchett GC, Mandaliya H, Bowden NA, van der Westhuizen A.
    Pharmacol Res Perspect; 2021 Aug; 9(4):e00808. PubMed ID: 34129290
    [Abstract] [Full Text] [Related]

  • 2. Retrospective analysis of treatment-naive Slovenian patients with metastatic melanoma treated with pembrolizumab - real-world experience.
    Hribernik N, Boc M, Ocvirk J, Knez-Arbeiter J, Mesti T, Ignjatovic M, Rebersek M.
    Radiol Oncol; 2020 Jan 19; 54(1):119-127. PubMed ID: 31955148
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial.
    Carlino MS, Long GV, Schadendorf D, Robert C, Ribas A, Richtig E, Nyakas M, Caglevic C, Tarhini A, Blank C, Hoeller C, Bar-Sela G, Barrow C, Wolter P, Zhou H, Emancipator K, Jensen EH, Ebbinghaus S, Ibrahim N, Daud A.
    Eur J Cancer; 2018 Sep 19; 101():236-243. PubMed ID: 30096704
    [Abstract] [Full Text] [Related]

  • 5. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001.
    Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph R, Weber JS, Dronca R, Mitchell TC, Patnaik A, Zarour HM, Joshua AM, Zhao Q, Jensen E, Ahsan S, Ibrahim N, Ribas A.
    Ann Oncol; 2019 Apr 01; 30(4):582-588. PubMed ID: 30715153
    [Abstract] [Full Text] [Related]

  • 6. Ex vivo modelling of PD-1/PD-L1 immune checkpoint blockade under acute, chronic, and exhaustion-like conditions of T-cell stimulation.
    Roberts A, Bentley L, Tang T, Stewart F, Pallini C, Juvvanapudi J, Wallace GR, Cooper AJ, Scott A, Thickett D, Lugg ST, Bancroft H, Hemming B, Ferris C, Langman G, Robinson A, Chapman J, Naidu B, Pinkney T, Taylor GS, Brock K, Stamataki Z, Brady CA, Curnow SJ, Gordon J, Qureshi O, Barnes NM.
    Sci Rep; 2021 Feb 17; 11(1):4030. PubMed ID: 33597595
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Real-world experience with pembrolizumab in patients with advanced melanoma: A large retrospective observational study.
    Liu FX, Ou W, Diede SJ, Whitman ED.
    Medicine (Baltimore); 2019 Jul 17; 98(30):e16542. PubMed ID: 31348273
    [Abstract] [Full Text] [Related]

  • 9. Pretreatment Glasgow prognostic score predicts survival among patients with high PD-L1 expression administered first-line pembrolizumab monotherapy for non-small cell lung cancer.
    Imai H, Kishikawa T, Minemura H, Yamada Y, Ibe T, Yamaguchi O, Mouri A, Hamamoto Y, Kanazawa K, Kasai T, Kaira K, Kaburagi T, Minato K, Kobayashi K, Kagamu H.
    Cancer Med; 2021 Oct 17; 10(20):6971-6984. PubMed ID: 34414673
    [Abstract] [Full Text] [Related]

  • 10. Pembrolizumab as first-line treatment for metastatic uveal melanoma.
    Rossi E, Pagliara MM, Orteschi D, Dosa T, Sammarco MG, Caputo CG, Petrone G, Rindi G, Zollino M, Blasi MA, Cassano A, Bria E, Tortora G, Schinzari G.
    Cancer Immunol Immunother; 2019 Jul 17; 68(7):1179-1185. PubMed ID: 31175402
    [Abstract] [Full Text] [Related]

  • 11. Pembrolizumab Utilization and Clinical Outcomes Among Patients With Advanced Melanoma in the US Community Oncology Setting: An Updated Analysis.
    Cowey CL, Scherrer E, Boyd M, Aguilar KM, Beeks A, Krepler C.
    J Immunother; 2019 Jul 17; 44(6):224-233. PubMed ID: 33734142
    [Abstract] [Full Text] [Related]

  • 12. Real-world efficacy of anti-PD-1 antibody or combined anti-PD-1 plus anti-CTLA-4 antibodies, with or without radiotherapy, in advanced mucosal melanoma patients: A retrospective, multicenter study.
    Umeda Y, Yoshikawa S, Kiniwa Y, Maekawa T, Yamasaki O, Isei T, Matsushita S, Nomura M, Nakai Y, Fukushima S, Saito S, Takenouchi T, Tanaka R, Kato H, Otsuka A, Matsuya T, Baba N, Nagase K, Inozume T, Onuma T, Kuwatsuka Y, Fujimoto N, Kaneko T, Onishi M, Namikawa K, Yamazaki N, Nakamura Y.
    Eur J Cancer; 2021 Nov 17; 157():361-372. PubMed ID: 34563991
    [Abstract] [Full Text] [Related]

  • 13. Pembrolizumab Utilization and Outcomes for Advanced Melanoma in US Community Oncology Practices.
    Cowey CL, Liu FX, Black-Shinn J, Stevinson K, Boyd M, Frytak JR, Ebbinghaus SW.
    J Immunother; 2018 Nov 17; 41(2):86-95. PubMed ID: 29252916
    [Abstract] [Full Text] [Related]

  • 14. PDCD1 Polymorphisms May Predict Response to Anti-PD-1 Blockade in Patients With Metastatic Melanoma.
    Parakh S, Musafer A, Paessler S, Witkowski T, Suen CSNLW, Tutuka CSA, Carlino MS, Menzies AM, Scolyer RA, Cebon J, Dobrovic A, Long GV, Klein O, Behren A.
    Front Immunol; 2021 Nov 17; 12():672521. PubMed ID: 34177913
    [Abstract] [Full Text] [Related]

  • 15. Overt Thyroid Dysfunction and Anti-Thyroid Antibodies Predict Response to Anti-PD-1 Immunotherapy in Cancer Patients.
    Basak EA, van der Meer JWM, Hurkmans DP, Schreurs MWJ, Oomen-de Hoop E, van der Veldt AAM, Bins S, Joosse A, Koolen SLW, Debets R, Peeters RP, Aerts JGJV, Mathijssen RHJ, Medici M.
    Thyroid; 2020 Jul 17; 30(7):966-973. PubMed ID: 32151195
    [Abstract] [Full Text] [Related]

  • 16. Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
    André T, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt C, Smith D, Garcia-Carbonero R, Benavides M, Gibbs P, de la Fouchardiere C, Rivera F, Elez E, Bendell J, Le DT, Yoshino T, Van Cutsem E, Yang P, Farooqui MZH, Marinello P, Diaz LA, KEYNOTE-177 Investigators.
    N Engl J Med; 2020 Dec 03; 383(23):2207-2218. PubMed ID: 33264544
    [Abstract] [Full Text] [Related]

  • 17. Metastatic melanoma patient outcomes since introduction of immune checkpoint inhibitors in England between 2014 and 2018.
    Board R, Smittenaar R, Lawton S, Liu H, Juwa B, Chao D, Corrie P.
    Int J Cancer; 2021 Feb 15; 148(4):868-875. PubMed ID: 32838478
    [Abstract] [Full Text] [Related]

  • 18. The efficacy of anti-programmed cell death protein 1 therapy among patients with metastatic acral and metastatic mucosal melanoma.
    Ogata D, Haydu LE, Glitza IC, Patel SP, Tawbi HA, McQuade JL, Diab A, Ekmekcioglu S, Wong MK, Davies MA, Amaria RN.
    Cancer Med; 2021 Apr 15; 10(7):2293-2299. PubMed ID: 33686688
    [Abstract] [Full Text] [Related]

  • 19. Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma.
    Ribas A, Hamid O, Daud A, Hodi FS, Wolchok JD, Kefford R, Joshua AM, Patnaik A, Hwu WJ, Weber JS, Gangadhar TC, Hersey P, Dronca R, Joseph RW, Zarour H, Chmielowski B, Lawrence DP, Algazi A, Rizvi NA, Hoffner B, Mateus C, Gergich K, Lindia JA, Giannotti M, Li XN, Ebbinghaus S, Kang SP, Robert C.
    JAMA; 2016 Apr 19; 315(15):1600-9. PubMed ID: 27092830
    [Abstract] [Full Text] [Related]

  • 20. First-line treatment of advanced/metastatic melanoma with anti-PD-1 antibodies: multicenter experience in Poland.
    Cybulska-Stopa B, Pacholczak-Madej R, Kamińska-Winciorek G, Ziętek M, Czarnecka AM, Piejko K, Galus Ł, Ziółkowska B, Kieszko S, Kempa-Kamińska N, Calik J, Rolski J, Sałek-Zań A, Gajewska-Wicher K, Drosik-Kwaśniewska A, Rogala P, Kubiatowski T, Suwiński R, Mackiewicz J, Rutkowski P.
    Immunotherapy; 2021 Mar 19; 13(4):297-307. PubMed ID: 33353420
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.